NCT03894540: Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least one line of therapy for advanced disease
Exclusions: Patients with symptomatic central nervous system metastasis

Comments are closed.

Up ↑